Literature DB >> 21142919

Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.

Fabienne Thomas1, Janelle M Hoskins, Anne Dvorak, Benjamin R Tan, Howard L McLeod.   

Abstract

AIMS: Polymorphisms in the 5' regulatory region of the thymidylate synthase gene (TYMS) have been shown to modulate thymidylate synthase expression and are associated with resistance to fluoropyrimidine-based therapies. These polymorphisms include a two repeat (2R) or three repeat (3R) of a 28-bp sequence and a G>C SNP in the second repeat of the 3R allele (TSER*3 G>C). Genotyping methods for the TYMS 5'-UTR polymorphisms have typically involved visualizing PCR and RFLP products on agarose gels. This article describes the use of a robust capillary electrophoresis assay for TYMS 5'-UTR genotyping. MATERIALS &
METHODS: As part of pharmacogenetic studies, we performed TYMS genotyping for the 5'-UTR polymorphisms in 314 colorectal cancer patients. A gel-based capillary electrophoresis method, employing a high-resolution gel cartridge on a QIAxcel(®) system, was developed to detect PCR products and RFLP fragment sizes.
RESULTS: The high resolution of the capillary electrophoresis technique allowed identification of a 6-bp insertion in the second repeat of the 3R allele in three patients. The frequency of the insertion allele was 0.4% in Caucasians and 1.3% in African-Americans. We also found 3.3% of Caucasian patients were heterozygous for a G>C SNP in the first repeat of the 2R allele, but this allele was not observed in the African-American patients.
CONCLUSION: We describe a robust RFLP genotyping technique that employs size discrimination by capillary electrophoresis to genotype the TYMS TSER*3 G>C SNP. The technique also allows identification of a 6-bp insertion in the 3R allele, and we report the allelic frequencies for two uncommon TSER alleles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21142919      PMCID: PMC3128643          DOI: 10.2217/pgs.10.170

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  18 in total

1.  Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).

Authors:  Su-Ryang Kim; Shogo Ozawa; Yoshiro Saito; Kouichi Kurose; Nahoko Kaniwa; Naoyuki Kamatani; Tetsuya Hamaguchi; Kuniaki Shirao; Manabu Muto; Atsushi Ohtsu; Teruhiko Yoshida; Yasuhiro Matsumura; Nagahiro Saijo; Jun-ichi Sawada
Journal:  Drug Metab Pharmacokinet       Date:  2006-12       Impact factor: 3.614

2.  Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele.

Authors:  Lisa F Lincz; Fiona E Scorgie; Madhu B Garg; Stephen P Ackland
Journal:  Int J Cancer       Date:  2007-05-01       Impact factor: 7.396

3.  p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.

Authors:  H J Lenz; K D Danenberg; C G Leichman; B Florentine; P G Johnston; S Groshen; L Zhou; Y P Xiong; P V Danenberg; L P Leichman
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

4.  Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA.

Authors:  S Kaneda; K Takeishi; D Ayusawa; K Shimizu; T Seno; S Altman
Journal:  Nucleic Acids Res       Date:  1987-02-11       Impact factor: 16.971

5.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

Authors:  S Marsh; E S Collie-Duguid; T Li; X Liu; H L McLeod
Journal:  Genomics       Date:  1999-06-15       Impact factor: 5.736

6.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

Authors:  C G Leichman; H J Lenz; L Leichman; K Danenberg; J Baranda; S Groshen; W Boswell; R Metzger; M Tan; P V Danenberg
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

7.  A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele.

Authors:  M Gusella; C Bolzonella; G Crepaldi; E Ferrazzi; R Padrini
Journal:  Pharmacogenomics J       Date:  2006-07-25       Impact factor: 3.550

8.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.

Authors:  H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase.

Authors:  N Horie; H Aiba; K Oguro; H Hojo; K Takeishi
Journal:  Cell Struct Funct       Date:  1995-06       Impact factor: 2.212

10.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.

Authors:  P G Johnston; H J Lenz; C G Leichman; K D Danenberg; C J Allegra; P V Danenberg; L Leichman
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

View more
  5 in total

1.  A capillary electrophoresis method for genotyping the 9-bp exon 1 insertion/deletion in BDKRB2.

Authors:  Jasmine Talameh; Anne Misher; Janelle Hoskins
Journal:  Pharmacogenomics       Date:  2012-02       Impact factor: 2.533

2.  The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.

Authors:  Moh'd Khushman; Girijesh Kumar Patel; Anu Singh Maharjan; Gwendolyn A McMillin; Cindy Nelson; Peter Hosein; Ajay P Singh
Journal:  Pharmacogenomics J       Date:  2021-02-19       Impact factor: 3.550

3.  Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.

Authors:  F Thomas; A A Motsinger-Reif; J M Hoskins; A Dvorak; S Roy; A Alyasiri; R J Myerson; J W Fleshman; B R Tan; H L McLeod
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

4.  Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis.

Authors:  Emilia Balboa-Beltrán; Raquel Cruz; Angel Carracedo; Francisco Barros
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

5.  Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).

Authors:  Jai N Patel; Chen Jiang; Kouros Owzar; Flora Mulkey; Jasmine A Luzum; Harvey J Mamon; Daniel G Haller; Tomislav Dragovich; Steven R Alberts; Georg Bjarnason; Christopher G Willet; Donna Niedzwiecki; Peter Enzinger; Mark J Ratain; Charles Fuchs; Howard L McLeod
Journal:  Pharmacogenet Genomics       Date:  2021-12-01       Impact factor: 2.089

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.